Efficacy and tolerability of first line ketogenic diet versus high dose adrenocorticotrophic hormone therapy and infantile spasm syndrome: An open label randomised controlled trial

被引：0

作者：

Mahesan, A. ^{[1
]}

Sondhi, V. ^{[2
]}

Agarwala, A. ^{[3
]}

Gupta, K. L. ^{[3
]}

Kamila, G. ^{[1
]}

Jauhari, P. ^{[1
]}

Chakrabarty, B. ^{[1
]}

Pandey, R. M. ^{[4
]}

Gulati, S. ^{[1
]}

机构：

[1] All India Inst Med Sci, Child Neurol Div, Pediat, New Delhi, India

[2] AFMC, Pediat, Pune, Maharashtra, India

[3] All India Inst Med Sci, Senior Dietician, Pediat, New Delhi, India

[4] All India Inst Med Sci, Biostatist, New Delhi, India

来源：

EPILEPSIA | 2024年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

457

引用

页码：381 / 381

页数：1

共 50 条

[41] Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04) a randomised, multicentre, open-label phase 3 trial
Pautier, Patricia
Italiano, Antoine
Piperno-Neumann, Sophie
Chevreau, Christine
Penel, Nicolas
Firmin, Nelly
Boudou-Rouquette, Pascaline
Bertucci, Francois
Balleyguier, Corinne
Lebrun-Ly, Valerie
Ray-Coquard, Isabelle
Kalbacher, Elsa
Bardet, Aurelie
Bompas, Emmanuelle
Collard, Olivier
Isambert, Nicolas
Guillemet, Cecile
Rios, Maria
Archambaud, Baptiste
Duffaud, Florence
LANCET ONCOLOGY, 2022, 23 (08): : 1044 - 1054
[42] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Thatcher, Nick
Hirsch, Fred R.
Luft, Alexander V.
Szczesna, Aleksandro
Ciuleanu, Tudor E.
Dediu, Mircea
Ramlau, Rodryg
Galiulin, Rinat K.
Balint, Beatrix
Losonczy, Gyoergy
Kazarnowicz, Andrzej
Park, Keunchil
Schumann, Christian
Reck, Martin
Depenbrock, Henrik
Nanda, Shivani
Letunic, Anamarija Kruljac
Kurek, Raffacl
Paz-Ares, Luis
Socinskf, Mark A.
LANCET ONCOLOGY, 2015, 16 (07): : 763 - 774
[43] HIGH VERSUS LOW DOSE ERYTHROPOIESIS-STIMULATING AGENTS IN PEOPLE WITH END-STAGE KIDNEY DISEASE TREATED WITH HAEMODIALYSIS (CE DOSE): AN OPEN-LABEL, PRAGMATIC, MULTICENTRE, PARALLEL-GROUP RANDOMISED CONTROLLED TRIAL
Saglimbene, Valeria
Palmer, Suetonia
Ruospo, Marinella
Williams, Gabrielle
Craig, Jonathan
Hegbrant, Jorgen
Strippoli, Giovanni
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1540 - 1540
[44] Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Gu, Weijie
Han, Weiqing
Luo, Hong
Zhou, Fangjian
He, Dalin
Ma, Lulin
Guo, Hongqian
Liang, Chaozhao
Chong, Tie
Jiang, Jun
Chen, Zhiwen
Wang, Yong
Zou, Qing
Tian, Ye
Xiao, Jun
Huang, Jian
Zhu, Shaoxing
Dong, Qiang
Zhang, Xiaoping
Li, Hanzhong
Yang, Xinfeng
Chen, Chunxia
Li, Junliang
Jin, Chunlei
Zhang, Xiaojing
Ye, Dingwei
LANCET ONCOLOGY, 2022, 23 (10): : 1249 - 1260
[45] High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial
Vourc'h, Mickael
Huard, Donatien
Le Penndu, Marguerite
Deransy, Romain
Surbled, Marielle
Malidin, Maelle
Mahe, Pierre-Joachim
Guitton, Christophe
Roquilly, Antoine
Malard, Olivier
Feuillet, Fanny
Rozec, Bertrand
Asehnoune, Karim
ECLINICALMEDICINE, 2023, 60
[46] Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Hu, Xi-Chun
Zhang, Jian
Xu, Bing-He
Cai, Li
Ragaz, Joseph
Wang, Zhong-Hua
Wang, Bi-Yun
Teng, Yue-E
Tong, Zhong-Sheng
Pan, Yue-Yin
Yin, Yong-Mei
Wu, Chang-Ping
Jiang, Ze-Fei
Wang, Xiao-Jia
Lou, Gu-Yin
Liu, Dong-Geng
Feng, Ji-Feng
Luo, Jian-Feng
Sun, Kang
Gu, Ya-Jia
Wu, Jiong
Shao, Zhi-Min
LANCET ONCOLOGY, 2015, 16 (04): : 436 - 446
[47] S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
Kang, Yoon-Koo
Chin, Keisho
Chung, Hyun Cheol
Kadowaki, Shigenori
Oh, Sang Cheul
Nakayama, Norisuke
Lee, Keun-Wook
Hara, Hiroki
Chung, Ik-Joo
Tsuda, Masahiro
Park, Se Hoon
Hosaka, Hisashi
Hironaka, Shuichi
Miyata, Yoshinori
Ryu, Min-Hee
Baba, Hideo
Hyodo, Ichinosuke
Bang, Yung-Jue
Boku, Narikazu
LANCET ONCOLOGY, 2020, 21 (08): : 1045 - 1056
[48] Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Sagara, Issaka
Beavogui, Abdoul Habib
Zongo, Issaka
Soulama, Issiaka
Borghini-Fuhrer, Isabelle
Fofana, Bakary
Traore, Aliou
Diallo, Nouhoum
Diakite, Hamadoun
Togo, Amadou H.
Koumare, Sekou
Keita, Mohamed
Camara, Daouda
Some, Anyirekun F.
Coulibaly, Aboubacar S.
Traore, Oumar B.
Dama, Souleymane
Goita, Siaka
Djimde, Moussa
Bamadio, Amadou
Dara, Niawanlou
Maiga, Hamma
Sidibe, Bouran
Dao, Francois
Coulibaly, Moctar
Alhousseini, Mohamed Laraine
Niangaly, Hamidou
Sangare, Boubou
Diarra, Modibo
Coumare, Samba
Kabore, Moise J. T.
Ouattara, San Maurice
Barry, Aissata
Kargougou, Desire
Diarra, Amidou
Henry, Noelie
Sore, Harouna
Bougouma, Edith C.
Thera, Ismaila
Compaore, Yves D.
Sutherland, Colin J.
Sylla, Malick Minkael
Nikiema, Frederic
Diallo, Mamadou Saliou
Dicko, Alassane
Picot, Stephane
Borrmann, Steffen
Duparc, Stephan
Miller, Robert M.
Doumbo, Ogobara K.
LANCET, 2018, 391 (10128): : 1378 - 1390
[49] First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
Babiker, Abdel
Castro , Hannah
Compagnucci, Alexandra
Fiscus, Susan
Giaquinto, Carlo
Gibb, Diana M.
Harper, Lynda
Harrison, Linda
Hughes, Michael
McKinney, Ross
Melvin, Ann
Mofenson, Lynne
Saidi, Yacine
Smith, M. Elizabeth
Tudor-Williams, Gareth
Walker, A. Sarah
LANCET INFECTIOUS DISEASES, 2011, 11 (04): : 273 - 283
[50] Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
Liou, Jyh-Ming
Jiang, Xiao-Tao
Chen, Chieh-Chang
Luo, Jiing-Chyuan
Bair, Ming-Jong
Chen, Po-Yueh
Chou, Chu-Kuang
Fang, Yu-Jen
Chen, Mei-Jyh
Chen, Chien-Chuan
Lee, Ji-Yuh
Yang, Tsung-Hua
Yu, Chien-Chun
Kuo, Chia-Chi
Chiu, Min-Chin
Chen, Chi-Yi
Shun, Chia-Tung
Hu, Wen-Hao
Tsai, Min-Horn
Hsu, Yao-Chun
Tseng, Cheng-Hao
Chang, Chi-Yang
Lin, Jaw-Town
El-Omar, Emad M.
Wu, Ming-Shiang
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (03): : 228 - 241

← 1 2 3 4 5 →